Page 4 - Brian Markison News Today

About Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Companys ophthalmic subsidiary supporting UPNEEQ. Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the Companys non-promoted products, including compl...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Osmotica to Present at 10th Annual SVB Leerink Global Healthcare Conference Osmotica Holdings US LLCFebruary 18, 2021 GMT BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Of...

Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets Osmotica Holdings US LLC Bridgewater, New Jersey, UNITED STATES BRIDGEWATER, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) regarding th...